dasolampanel etibutil
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00790790)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Metabotropic glutamate receptor 5ANTAGONIST
GRM5 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCC(CC)COC(=O)[C@@H]1C[C@H]2C[C@@H](Oc3cccc(Cl)c3-c3nnn[nH]3)CC[C@H]2CN1- Mol. weight
- 461.99 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545161 ↗
- ChEMBLCHEMBL2107328 ↗
Also known as
- dasolampanel etibutil
- dasolampanel etibutil
- ly545694
- ly545694
- ly545694
- ly545694
- ly-545694
- ly-545694
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00785577 | Phase 2 | Nov 1, 2008 | Eli Lilly |
| NCT00790790 | Phase 2 | Nov 1, 2008 | Eli Lilly |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 2 | 1 | 2008 |
1 organizations
Page 1 / 1